Department of Chest Disease, Sureyyapasa Chest Disease and Thoracic Surgery Training and Research Hospital, Goktepe Sokak, No 2/14, Feneryolu, Istanbul, Turkey.
Med Oncol. 2010 Jun;27(2):237-41. doi: 10.1007/s12032-009-9198-8. Epub 2009 Apr 28.
The current prognosis in patients with small cell lung cancer (SCLC) is unsatisfactory, even though there have been considerable improvements in diagnosis and treatment.
We retrospectively analyzed all consecutive patients with small cell lung carcinoma between 1995 and 2007 in a Turkish chest hospital. A total of 116 SCLC patients initially presented with limited disease, while 92 small cell lung carcinoma patients were found to be extensive.
The mean age of the patients (18 women and 190 men) was 56 years. The median survival was 74 weeks. Performance status, superior vena cava syndrome (SVCS), stage, elevated white blood cell count, elevated lactate dehidrogenase levels, short symptom duration (<or=4 weeks) response to chemotherapy and bone metastasis were significant prognostic factors in univariate analysis. It was necessary for patients to receive at least three cycles of chemotherapy for a survival benefit. Cox proportional hazards model identified only stage, performance status and SVCS as independent prognostic factors.
Stage, performance status and SVCS were determined to be the most important prognostic factors for SCLC patients.
尽管在小细胞肺癌（SCLC）的诊断和治疗方面已经取得了相当大的进展，但患者的预后仍然不尽如人意。
我们回顾性分析了 1995 年至 2007 年间在一家土耳其胸科医院就诊的所有连续小细胞肺癌患者。共有 116 例 SCLC 患者最初表现为局限性疾病，92 例小细胞肺癌患者为广泛性疾病。
患者的平均年龄（18 名女性和 190 名男性）为 56 岁。中位生存期为 74 周。在单因素分析中，体能状态、上腔静脉综合征（SVCS）、分期、白细胞计数升高、乳酸脱氢酶水平升高、症状持续时间短（≤4 周）、对化疗的反应和骨转移是显著的预后因素。患者需要接受至少 3 个周期的化疗才能获得生存获益。Cox 比例风险模型仅确定了分期、体能状态和 SVCS 为独立的预后因素。
分期、体能状态和 SVCS 被确定为 SCLC 患者最重要的预后因素。
